ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

作者
DW Lee,BD Santomasso,FL Locke,Armin Ghobadi,Cameron John Turtle,Jennifer N. Brudno,Marcela Valderrama Maus,Jin‐hong Park,Edward A. Mead,Steven Zivko Pavletic,WY Go,Lamis K. Eldjerou,RA Gardner,Noelle V. Frey,Kevin Curran,Karl S. Peggs,Marcelo C. Pasquini,JF DiPersio,Mrm van den Brink,Krishna V. Komanduri
出处
期刊:University College London - UCL Discovery [University College London]
被引量:24
摘要

Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematologic malignancies. Two CAR T products were recently approved in the United States and Europe for the treatment of patients up to age 25 years with relapsed or refractory B cell acute lymphoblastic leukemia years "?>and/or adults with large B cell lymphoma. Many more CAR T products, as well as other immunotherapies, including various immune cell- and bi-specific antibody-based approaches that function by activation of immune effector cells, are in clinical development for both hematologic and solid tumor malignancies. These therapies are associated with unique toxicities of cytokine release syndrome (CRS) and neurologic toxicity. The assessment and grading of these toxicities vary considerably across clinical trials and across institutions, making it difficult to compare the safety of different products and hindering the ability to develop optimal strategies for management of these toxicities. Moreover, some aspects of these grading systems can be challenging to implement across centers. Therefore, in an effort to harmonize the definitions and grading systems for CRS and neurotoxicity, experts from all aspects of the field met on June 20 and 21, 2018, at a meeting supported by the American Society for Blood and Marrow Transplantation (ASBMT) in Arlington, VA. Here we report the consensus recommendations of that group and propose new definitions and grading for CRS and neurotoxicity that are objective, easy to apply, and ultimately more accurately categorize the severity of these toxicities. The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
于归故城完成签到,获得积分10
刚刚
zbs完成签到,获得积分10
刚刚
songshu完成签到,获得积分10
刚刚
丫丫完成签到,获得积分10
刚刚
。。完成签到,获得积分10
1秒前
威武的友菱完成签到,获得积分10
1秒前
宇宙无敌暴龙战士完成签到 ,获得积分10
2秒前
2秒前
sjdd完成签到 ,获得积分10
2秒前
乐乐的应助被科研通管家采纳,获得10
2秒前
飞飞的应助被科研通管家采纳,获得30
2秒前
汉堡包的应助被科研通管家采纳,获得10
2秒前
lucky完成签到,获得积分10
3秒前
无花果的应助被科研通管家采纳,获得30
3秒前
文文的应助被科研通管家采纳,获得10
3秒前
su完成签到,获得积分10
3秒前
俭朴迎荷完成签到,获得积分10
3秒前
桐桐的应助被科研通管家采纳,获得10
3秒前
梨子完成签到,获得积分10
3秒前
打打的应助被科研通管家采纳,获得10
3秒前
jingwen完成签到,获得积分10
3秒前
英俊的铭的应助被科研通管家采纳,获得10
3秒前
kuaile的雯完成签到 ,获得积分10
3秒前
路人完成签到,获得积分10
3秒前
打打的应助被科研通管家采纳,获得10
3秒前
大卫完成签到,获得积分10
3秒前
Ava的应助被科研通管家采纳,获得10
3秒前
飞飞的应助被科研通管家采纳,获得40
3秒前
飞飞的应助被科研通管家采纳,获得10
4秒前
飞飞的应助被科研通管家采纳,获得10
4秒前
王慧完成签到,获得积分10
4秒前
天天快乐的应助被科研通管家采纳,获得10
4秒前
CC完成签到,获得积分10
4秒前
4秒前
莽哥完成签到,获得积分10
5秒前
byejack发布了新的文献求助10
5秒前
5秒前
ws完成签到,获得积分10
6秒前
墨鱼完成签到,获得积分10
6秒前
tmac完成签到 ,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039